Riskpilot← Back to searchSign inGet full accessClario Vision AB
ABActiveOrg 5566716303Törnhultsbacken 2Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20040 employees
Revenue 2025
SEK 1,2M
+13% vs 2024
EBITDA margin
92.9%
+32% vs 2024
Equity ratio
99.0%
Financial strength
Net profit 2025
SEK 843K
+33% vs 2024
| Revenue | SEK 1,2M | +13% |
| EBITDA | SEK 1,1M | +32% |
| Net profit | SEK 843K | +33% |
| Total assets | SEK 6,3M | +16% |
| Equity | SEK 6,2M | +16% |
| Employees | 0 | — |
Legal name
Clario Vision AB
Org number
5566716303
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
3 december 2004
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna suppleanten
Company purpose
Bolaget skall marknadsföra och försälja läkemedel i de nordiska länderna.
Address
Törnhultsbacken 2
Phone
+4687659725
Email
omnivisionab@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 717 | 1 338 | 1 296 | 1 017 | 1 151 |
| Staff expenses | — | −0 | — | — | — |
| EBITDA | 579 | 1 264 | 1 122 | 811 | 1 070 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 579 | 1 264 | 1 122 | 811 | 1 070 |
| Net financials | — | 0 | 2 | −4 | −0 |
| Profit before tax | 579 | 1 264 | 1 123 | 807 | 1 069 |
| Tax | −124 | −266 | −234 | −172 | −226 |
| Net profit | 455 | 999 | 889 | 635 | 843 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 249 | 4 221 | 4 993 | 5 391 | 6 254 |
| Equity | 3 208 | 4 019 | 4 713 | 5 348 | 6 191 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 40 | 202 | 279 | 43 | 63 |
| Total debt | 40 | 202 | 279 | 43 | 63 |
EBITDA margin
92.9%
This company
15.8%
Market median
+488% vs market
20212025
Equity ratio
99.0%
This company
38.2%
Market median
+159% vs market
20212025
Return on equity
13.6%
This company
18.4%
Market median
+26% vs market
20212025
Net profit margin
73.2%
This company
8.1%
Market median
+804% vs market
20212025
Asset turnover
0.18×
This company
1.12×
Market median
-84% vs market
20212025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
IM Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (1) | ||
BM | Audit | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2020 | |
| Chairman | 2020 | |
| Former (1) | ||
| Deputy Board Member | 2022 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Clario Vision AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ida Maria Elisabeth Lindholm | Chief Executive Officer | 0 companies |
| Bodil Marianne Nordin | Audit | 0 companies |
| Sara Inez Elisabeth Lindholm | Deputy Board Member | 0 companies |
| Annika Iréne Lindholm | Deputy Board Member | 0 companies |
| Bo Magnus Lindholm | Chairman | 0 companies |